ストックスクリーナーアプリを入手
4.12
11.35%
0.42
アフターアワーズ：
4.05
-0.07
-1.70%
前日終値:
$3.70
開ける：
$3.62
24時間の取引高:
49,811
Relative Volume:
1.63
時価総額：
$192.71M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+15.08%
1か月 パフォーマンス:
+1.48%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$3.6001
$4.285
1週間の範囲:
$3.4341
$4.285
52週間の値動き範囲:
$3.4341
$4.8816
Capsovision Inc Stock (CV) Company Profile
CV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CV
Capsovision Inc
|
4.12 | 169.79M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
133.73 | 225.15B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.71 | 155.92B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
383.34 | 146.41B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
94.03 | 118.42B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
77.57 | 45.96B | 5.69B | 1.41B | 577.90M | 6.95 |
Capsovision Inc Stock (CV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-28 | 開始されました | Roth Capital | Buy |
| 2025-07-28 | 開始されました | The Benchmark Company | Speculative Buy |
Capsovision Inc (CV) 最新ニュース
CapsoVision (NASDAQ:CV) Trading Down 2.2%Here's What Happened - MarketBeat
Financial Analysis: Longevity Health (NASDAQ:XAGE) versus CapsoVision (NASDAQ:CV) - Defense World
CapsoVision CFO Kevin Lundquist Steps Down - TipRanks
CapsoVision chief financial officer steps down; company begins search for successor - Investing.com
CapsoVision CFO Kevin Lundquist Resigns - MarketWatch
Capsovision says Kevin Lundquist steps down as CFOSEC filing - MarketScreener
Ingestible Sensors Market Set for Dynamic Growth with Key Players CapsoVision, Inc., BodyCAP, etectRx - openPR.com
Head to Head Comparison: CapsoVision (NASDAQ:CV) vs. ReShape Lifesciences (OTCMKTS:RSLSD) - Defense World
Smart Pills Market Worth US$1.30 Billion By 2030 With 11.2% CAGR - Barchart.com
Smart Pills Market worth US$1.30 billion by 2030 with 11.2% CAGR - openPR.com
FY2028 EPS Estimates for CapsoVision Lowered by Roth Capital - MarketBeat
Critical Analysis: CapsoVision (NASDAQ:CV) vs. ReShape Lifesciences (OTCMKTS:RSLSD) - Defense World
Insider Transactions Reported | CapsoVision(CV)saw insider trading activity on 8/22/2025 - AInvest
FY2028 EPS Estimates for CapsoVision Cut by Roth Capital - Defense World
CapsoVision (NASDAQ:CV) Issues Earnings Results - MarketBeat
CapsoVision 2025 Q2 Earnings Net Loss Narrows 12.2% - AInvest
CapsoVision Reports Second Quarter 2025 Financial Results - GlobeNewswire
CapsoVision Reports Revenue Growth and IPO Success - TipRanks
CapsoVision Revenue Jumps 17 Percent - AOL.com
Smart Pills Company Evaluation Report 2025 | Medtronic, Olympus, and CapsoVision Lead with Minimally Invasive and AI-Enhanced Medical Technologies - Yahoo Finance
CapsoVision (NASDAQ:CV) versus ReShape Lifesciences (OTCMKTS:RSLSD) Head to Head Comparison - Defense World
Reviewing ReShape Lifesciences (OTCMKTS:RSLSD) and CapsoVision (NASDAQ:CV) - Defense World
CapsoVision, Inc.'s Quiet Period Set To Expire on August 11th (NASDAQ:CV) - MarketBeat
CapsoVision, Inc.’s (NASDAQ:CV) Quiet Period Will End on August 11th - Defense World
Is capsovision scam - AInvest
Roth Capital Predicts CapsoVision's Q2 Earnings (NASDAQ:CV) - MarketBeat
CapsoVision (NASDAQ:CV) Raised to Strong-Buy at Roth Capital - MarketBeat
Understanding the risks associated with CapsoVision's stock - AInvest
CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - GlobeNewswire
Capsovision, Inc. shares fall 2.19% intraday as Kioxia Corporation announces new UFS 4.1 devices for automotive applications. - AInvest
Q2 Earnings Estimate for CapsoVision Issued By Roth Capital - Defense World
Roth Capital Upgrades CapsoVision (NASDAQ:CV) to Strong-Buy - Defense World
CapsoVision (NASDAQ:CV) Rating Increased to Strong-Buy at Roth Capital - Defense World
CapsoVision (NASDAQ:CV) Upgraded at Roth Capital - Defense World
CapsoVision (NASDAQ:CV) Upgraded by Roth Capital to Strong-Buy Rating - Defense World
CapsoVision (NASDAQ:CV) Raised to “Strong-Buy” at Roth Capital - Defense World
Capsovision, Inc. shares rise 3.45% intraday after Canon Inc. announces share buyback plan. - AInvest
CapsoVision is a buy, this analyst says - Cantech Letter
Capsovision, Inc. shares fall 1.15% premarket after Canon Inc. announced a buyback plan. - AInvest
CapsoVision (NASDAQ:CV) Earns Speculative Buy Rating from Analysts at Benchmark - MarketBeat
Benchmark Co. Initiates CapsoVision(CV.US) With Buy Rating, Announces Target Price $5 - 富途牛牛
CapsoVision: Benchmark initiates coverage with Speculative Buy rating, $5 price target. - AInvest
CapsoVision stock initiated with Speculative Buy rating at Benchmark By Investing.com - Investing.com Australia
Benchmark starts CapsoVision with a Speculative Buy as CapsoCam Plus takes share - TipRanks
CapsoVision initiated with a Buy at Roth Capital - TipRanks
CapsoVision stock initiated with Buy rating at Roth/MKM on GI imaging potential - Investing.com Nigeria
CapsoVision Completes $27.5 Million Nasdaq IPO - Global Legal Chronicle
CapsoVision enters development agreement with Canon and announces partial IPO overallotment exercise - Investing.com India
Capsovision Inc (CV) 財務データ
Capsovision Inc (CV) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.14%
1.01%
大文字化:
|
ボリューム (24 時間):